dCBP-1

dCBP-1 is an experimental **small-molecule proteolysis-targeting chimera** that induces degradation of the lysine acetyltransferases p300 and CREB-binding protein by recruiting the E3 ubiquitin ligase cereblon. It was reported in preclinical research as a potent and selective p300/CBP degrader that suppresses enhancer-driven transcription, including oncogenic MYC-associated programs, and shows strong antiproliferative activity in multiple myeloma cell models. Based on the provided information, dCBP-1 appears to be a research compound described in the literature rather than a clinically developed pharmaceutical candidate, and no specific commercial drug developer, manufacturer for therapeutic use, or approved brand name has been identified.